The drug was identified as a potential COVID-19 treatment by researchers using supercomputers to screen more than 400,000 molecules for chemical characteristics that might inhibit the virus, focusing on those already approved for use in humans.
Andrea Beccari, from Excalate4Cov, a public-private consortium led by Italy’s Dompé Farmaceutici, said researchers hoped that raloxifene - a generic drug known as a selective oestrogen receptor modulator - would block replication of the virus in cells and thus slow down progress of the disease.
“It inhibits virus replication, thus preventing the worsening of patients with mild symptoms, and also decreases infectivity, limiting the viral load,” said Marco Allegretti, head of research at Dompé Farmaceutici.
The trial will involve 450 hospital and home patients at Rome’s Spallanzani Hospital and Humanitas in Milan in the initial phase.
They will be given a seven-day treatment of raloxifene capsules in a randomised sample and 174 more people may be added in the final stage. Enrolment will last 12 weeks.
The Excalate4Cov platform is backed by the European Commission and coordinates supercomputing centres in Italy, Germany and Spain with pharmaceutical companies and research centres, including the University of Louvain, Fraunhofer Institut, Politecnico di Milano and Spallanzani Hospital.
It uses a chemical library of 500 billion molecules and can process 3 million molecules per second using four supercomputers of more than 122 Petaflops, a unit of computing speed equal to one thousand trillion floating-point operations a second.
Researchers harnessed the power of the supercomputers to create a three-dimensional structure of 12 coronavirus proteins and conduct simulations to see where the proteins may be attacked by a drug.
“It took a million hours of calculation,” Beccari said, adding that, as research continued, it may be possible to develop second-generation drugs superior to raloxifene.
($1 = €0.8443)